Low-Density Lipoprotein and High-Density Lipoprotein as Biomarkers for Inflammatory Bowel Disease Activity Assessment.

Abstract

Purpose: To explore the correlation of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) with inflammatory bowel disease activity and their value in predicting disease activity.

Patients and methods: Clinical data of 490 adult IBD patients diagnosed in two IBD centers were collected, and 200 healthy people were served as controls. To evaluate the correlation of IDL and HDL with clinical and endoscopic activity of inflammatory bowel disease (IBD), and to explore the predictive value of them for disease activity.

Results: In CD, there were differences in HDL, CRP and ESR levels (p<0.001) among different disease activity groups. HDL levels were negatively correlated with HBI and CDEIS. In UC, there were differences in LDL, HDL, CRP and ESR levels among groups with different disease activities (p<0.001). Both LDL and HDL levels were negatively correlated with Mayo clinical score and UCEIS (p<0.001). The sensitivity of LDL for predicting moderate-severe UC was slightly higher than CRP (65.65% vs 60.31%). The specificity of HDL in predicting moderate-severe CD (65.85% vs 52.44%) and UC (87.34% vs 79.75%) was higher than CRP.

Conclusion: In patients with IBD, serum levels of both LDL and HDL were significantly lower compared to healthy controls. These levels correlated with disease activity. Furthermore, LDL and HDL levels demonstrated potential utility in distinguishing patients with moderate-severe IBD and show promise as monitoring biomarkers for IBD.